ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.9534del (p.Asn3178fs)

dbSNP: rs2073040366
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001039817 SCV001203365 pathogenic Hereditary breast ovarian cancer syndrome 2021-07-20 criteria provided, single submitter clinical testing This variant disrupts the C-terminus of the BRCA2 protein. Other variant(s) that disrupt this region (p.Tyr3308*) have been determined to be pathogenic (PMID: 18593900, 18607349, 17026620, 22711857). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with BRCA2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the BRCA2 gene (p.Asn3178Lysfs*39). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 241 amino acids of the BRCA2 protein.
Ambry Genetics RCV003283881 SCV004005451 pathogenic Hereditary cancer-predisposing syndrome 2023-05-16 criteria provided, single submitter clinical testing The c.9534delC pathogenic mutation, located in coding exon 25 of the BRCA2 gene, results from a deletion of one nucleotide at nucleotide position 9534, causing a translational frameshift with a predicted alternate stop codon (p.N3178Kfs*39). This alteration occurs at the 3' terminus of theBRCA2 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 7% of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.